Teva Pharmaceutical Industries Says FDA Approved WELTRUZA for Schizophrenia in Adults
MT newswire2026/10/09 11:3607:36 AM EDT, 10/09/2026 (MT Newswires) -- Teva Pharmaceutical Industries (TEVA) said Friday that the US Food and Drug Administration has approved WELTRUZA for extended-release injectable suspension of olanzapine for subcutaneous use as a treatment of schizophrenia in adults. The company said WELTRUZA will be available in the US in the coming weeks in once-monthly subcutaneous injectable doses of 318 mg, 425 mg and 531 mg. The injections will not require loading doses, oral supplementation, or post-injection monitoring, the company said. Teva said approval was based on results from its phase-3 Solaris trial, which showed a significant reduction in illness severity and improvement in personal and social functioning. The company said the treatment's safety profile was consistent with oral olanzapine, while reported adverse events included weight gain, sleepiness, headache, constipation and injection-site reactions. Shares of the company were up 3.4% in Friday's premarket activity.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Update: Equities Rise Intraday as Traders Parse Consumer Sentiment Survey
01:37 PM EDT, 10/09/2026 (MT Newswires) -- (Updates with latest market prices and developments.) US benchmark equity indexes were higher intraday as investors evaluated a survey on consumer sentiment. The Dow Jones Industrial Average was up 0.8% at 51,628.8 after midday Friday, while the Nasdaq Composite and the S&P 500 rose 0.6% each to 27,352.4 and 7,809.5, respectively. Barring communication services, all sectors were in the green, led by real estate. US consumer sentiment fell in October as the one- and five-year inflation expectations reached their highest levels since May, preliminary results of a University of Michigan survey showed Friday. "While year-ahead expectations for personal finances and business conditions crept up slightly, buying conditions for durables plummeted amid high prices and borrowing costs," Surveys of Consumers Director Joanne Hsu said. "Frustration over cost-of-living continues to mount, as consumers across the political spectrum believe that the trajectory of the economy has weakened since the beginning of the year." Markets are currently pricing in a nearly 81% probability that the Federal Reserve will keep its benchmark rate steady later this month, with the remaining odds in favor of a second consecutive 25-basis-point hike, as the central bank looks to tame inflation, according to the CME FedWatch tool. West Texas Intermediate crude was down 0.4% at $91.17 a barrel intraday, while Brent lost 0.5% to $103.81. The 10-year US Treasury yield was up 1.5 basis points at 5.25%, while the two-year rate increased 3.9 basis points to 4.8%. In company news, SpaceX (SPCX) shares were up 0.5%. The rocket and satellite company said late Thursday it agreed to acquire a nationwide low-band spectrum portfolio from investment firm Grain Management as it seeks to establish Starlink Mobile as a major US mobile carrier. T-Mobile US (TMUS) shares sank 13% intraday Friday, the worst performer on the S&P 500, followed by AT&T (T) and Verizon Communications (VZ), which fell 10% and 9.8%, respectively.
Ameren declares quarterly dividend of $0.75 a share
Ameren declared a quarterly cash dividend of 75 cents per common share. Dividend payable Dec. 31, 2026. Shareholders of record as of Dec. 8, 2026 will receive the dividend. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ameren Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610091331PR_NEWS_USPR_____CG68019) on October 09, 2026, and is solely responsible for the information contained therein.
McEwen’s $55M Ontario asset sale fuels gold growth plans
US Stock Market Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuts on the US stock market; shares fall over 10% after opening
As of press time, the stock has dropped more than 10%, trading at $10.77.